A model for analyzing the cost of the main clinical events after lung transplantation

L D Sharples, G J Taylor, J Karnon, N Caine, M Buxton, K McNeil, J Wallwork

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with these events, and to assess the economic impact of different immunosuppression therapies. Methods: The population comprised 356 lung transplant patients (223 heart-lung, 102 single lung and 31 double lung) transplanted between April 1984 and December 1997. AU patients received a cyclosporine-based triple-immunosuppression protocol. We designed a Markov model that included 3 time periods (0 to 6, 7 to 12, and 13 to 60 months), 5 clinical states (well, acute rejection, cytomegalovirus infection, non-cytomegalavirus infection and bronchiolitis obliterans syndrome), and death. For the well state, cost elements were immunosuppression, prophylaxis, and routine clinic visits. For all other states, cost elements were diagnosis, treatment, and bed days/visits. We excluded costs of the procedure. Results: The monthly costs associated with the well state decreased over time, from pound1,778 ($2,658) in the first 6 months to pound 503 ($752) in months 7 to 12 and pound 350 ($523) after the first 12 months. The cost per event of the acute states remained reasonably constant over the 3 periods: pound1,850 ($2,766) for rejection, pound3,380 ($5,053) for cytomegalovirus, and pound2,790 ($4,171) for other infections. The average cost per patient, discounted at 6%, over 5 years was pound 35,429 ($52,966) (95% range, pound1,435 [$2,145] to pound 67,079 [$100,283]). This estimate is most sensitive to changes in immunosuppression. Substituting tacrolimus for cyclosporine increased 5-year costs by 5%; substituting mycophenolate mofetil for azathioprine increased 5-year costs by 26%. Conclusions: This model is valuable in estimating the effect of new immunosuppression agents on the costs of follow-up care.
Original languageEnglish
Pages (from-to)474-482
Number of pages9
JournalJournal of Heart and Lung Transplantation
Volume20
Issue number4
Publication statusPublished - 2001

Fingerprint

Lung Transplantation
Costs and Cost Analysis
Immunosuppression
Lung
Transplants
Cyclosporine
Mycophenolic Acid
Bronchiolitis Obliterans
Aftercare
Azathioprine
Cytomegalovirus Infections
Tacrolimus
Ambulatory Care
Infection
Cytomegalovirus
Economics

Cite this

Sharples, L. D., Taylor, G. J., Karnon, J., Caine, N., Buxton, M., McNeil, K., & Wallwork, J. (2001). A model for analyzing the cost of the main clinical events after lung transplantation. Journal of Heart and Lung Transplantation, 20(4), 474-482.

A model for analyzing the cost of the main clinical events after lung transplantation. / Sharples, L D; Taylor, G J; Karnon, J; Caine, N; Buxton, M; McNeil, K; Wallwork, J.

In: Journal of Heart and Lung Transplantation, Vol. 20, No. 4, 2001, p. 474-482.

Research output: Contribution to journalArticle

Sharples, LD, Taylor, GJ, Karnon, J, Caine, N, Buxton, M, McNeil, K & Wallwork, J 2001, 'A model for analyzing the cost of the main clinical events after lung transplantation', Journal of Heart and Lung Transplantation, vol. 20, no. 4, pp. 474-482.
Sharples LD, Taylor GJ, Karnon J, Caine N, Buxton M, McNeil K et al. A model for analyzing the cost of the main clinical events after lung transplantation. Journal of Heart and Lung Transplantation. 2001;20(4):474-482.
Sharples, L D ; Taylor, G J ; Karnon, J ; Caine, N ; Buxton, M ; McNeil, K ; Wallwork, J. / A model for analyzing the cost of the main clinical events after lung transplantation. In: Journal of Heart and Lung Transplantation. 2001 ; Vol. 20, No. 4. pp. 474-482.
@article{3007724f36d34316b488ed43a9a1195f,
title = "A model for analyzing the cost of the main clinical events after lung transplantation",
abstract = "Background: The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with these events, and to assess the economic impact of different immunosuppression therapies. Methods: The population comprised 356 lung transplant patients (223 heart-lung, 102 single lung and 31 double lung) transplanted between April 1984 and December 1997. AU patients received a cyclosporine-based triple-immunosuppression protocol. We designed a Markov model that included 3 time periods (0 to 6, 7 to 12, and 13 to 60 months), 5 clinical states (well, acute rejection, cytomegalovirus infection, non-cytomegalavirus infection and bronchiolitis obliterans syndrome), and death. For the well state, cost elements were immunosuppression, prophylaxis, and routine clinic visits. For all other states, cost elements were diagnosis, treatment, and bed days/visits. We excluded costs of the procedure. Results: The monthly costs associated with the well state decreased over time, from pound1,778 ($2,658) in the first 6 months to pound 503 ($752) in months 7 to 12 and pound 350 ($523) after the first 12 months. The cost per event of the acute states remained reasonably constant over the 3 periods: pound1,850 ($2,766) for rejection, pound3,380 ($5,053) for cytomegalovirus, and pound2,790 ($4,171) for other infections. The average cost per patient, discounted at 6{\%}, over 5 years was pound 35,429 ($52,966) (95{\%} range, pound1,435 [$2,145] to pound 67,079 [$100,283]). This estimate is most sensitive to changes in immunosuppression. Substituting tacrolimus for cyclosporine increased 5-year costs by 5{\%}; substituting mycophenolate mofetil for azathioprine increased 5-year costs by 26{\%}. Conclusions: This model is valuable in estimating the effect of new immunosuppression agents on the costs of follow-up care.",
author = "Sharples, {L D} and Taylor, {G J} and J Karnon and N Caine and M Buxton and K McNeil and J Wallwork",
note = "ID number: ISI:000168040900012",
year = "2001",
language = "English",
volume = "20",
pages = "474--482",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - A model for analyzing the cost of the main clinical events after lung transplantation

AU - Sharples, L D

AU - Taylor, G J

AU - Karnon, J

AU - Caine, N

AU - Buxton, M

AU - McNeil, K

AU - Wallwork, J

N1 - ID number: ISI:000168040900012

PY - 2001

Y1 - 2001

N2 - Background: The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with these events, and to assess the economic impact of different immunosuppression therapies. Methods: The population comprised 356 lung transplant patients (223 heart-lung, 102 single lung and 31 double lung) transplanted between April 1984 and December 1997. AU patients received a cyclosporine-based triple-immunosuppression protocol. We designed a Markov model that included 3 time periods (0 to 6, 7 to 12, and 13 to 60 months), 5 clinical states (well, acute rejection, cytomegalovirus infection, non-cytomegalavirus infection and bronchiolitis obliterans syndrome), and death. For the well state, cost elements were immunosuppression, prophylaxis, and routine clinic visits. For all other states, cost elements were diagnosis, treatment, and bed days/visits. We excluded costs of the procedure. Results: The monthly costs associated with the well state decreased over time, from pound1,778 ($2,658) in the first 6 months to pound 503 ($752) in months 7 to 12 and pound 350 ($523) after the first 12 months. The cost per event of the acute states remained reasonably constant over the 3 periods: pound1,850 ($2,766) for rejection, pound3,380 ($5,053) for cytomegalovirus, and pound2,790 ($4,171) for other infections. The average cost per patient, discounted at 6%, over 5 years was pound 35,429 ($52,966) (95% range, pound1,435 [$2,145] to pound 67,079 [$100,283]). This estimate is most sensitive to changes in immunosuppression. Substituting tacrolimus for cyclosporine increased 5-year costs by 5%; substituting mycophenolate mofetil for azathioprine increased 5-year costs by 26%. Conclusions: This model is valuable in estimating the effect of new immunosuppression agents on the costs of follow-up care.

AB - Background: The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with these events, and to assess the economic impact of different immunosuppression therapies. Methods: The population comprised 356 lung transplant patients (223 heart-lung, 102 single lung and 31 double lung) transplanted between April 1984 and December 1997. AU patients received a cyclosporine-based triple-immunosuppression protocol. We designed a Markov model that included 3 time periods (0 to 6, 7 to 12, and 13 to 60 months), 5 clinical states (well, acute rejection, cytomegalovirus infection, non-cytomegalavirus infection and bronchiolitis obliterans syndrome), and death. For the well state, cost elements were immunosuppression, prophylaxis, and routine clinic visits. For all other states, cost elements were diagnosis, treatment, and bed days/visits. We excluded costs of the procedure. Results: The monthly costs associated with the well state decreased over time, from pound1,778 ($2,658) in the first 6 months to pound 503 ($752) in months 7 to 12 and pound 350 ($523) after the first 12 months. The cost per event of the acute states remained reasonably constant over the 3 periods: pound1,850 ($2,766) for rejection, pound3,380 ($5,053) for cytomegalovirus, and pound2,790 ($4,171) for other infections. The average cost per patient, discounted at 6%, over 5 years was pound 35,429 ($52,966) (95% range, pound1,435 [$2,145] to pound 67,079 [$100,283]). This estimate is most sensitive to changes in immunosuppression. Substituting tacrolimus for cyclosporine increased 5-year costs by 5%; substituting mycophenolate mofetil for azathioprine increased 5-year costs by 26%. Conclusions: This model is valuable in estimating the effect of new immunosuppression agents on the costs of follow-up care.

M3 - Article

VL - 20

SP - 474

EP - 482

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 4

ER -